NCT05022732

Polyglucosamine L112 in Overweight and Obese Subjects

Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Effect on Weight of a Medical Device Based on Polyglucosamine L112® in a Group of Overweight and Obese Subjects

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Azienda di Servizi alla Persona di Pavia · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This research proposes as its main purpose to evaluate the effectiveness of the intake of Polyglucosamine at a dose of 3 g / day on weight loss in a group of subjects suffering from overweight and mild obesity (BMI between 25 and 32 kg / m2). and with weight\> 75 kg

Conditions

• Obesity

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Polyglucosamine L112	750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients
COMBINATION_PRODUCT	Placebo	excipients and gum arabic

Timeline

• Start date: 2020-05-05
• Primary completion: 2020-08-05
• Completion: 2021-08-19
• First posted: 2021-08-26
• Last updated: 2021-08-26

Locations

1 site across 1 country: Italy